Tech Company Financing Transactions
ViroXis Funding Round
Texas Emerging Technology Fund invested in a $2.5 million venture round for ViroXis. The round was announced on 10/15/2010.
Transaction Overview
Company Name
Announced On
10/15/2010
Transaction Type
Venture Equity
Amount
$2,500,000
Round
Undisclosed
Investors
Proceeds Purpose
The capital will be used to advance development and commercialization of San Antonio, Texas-based ViroXis' topical Albuterpenoid anti-viral treatment of skin warts.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
18618 Tuscany Stone Dr. 100
San Antonio, TX 78258
USA
San Antonio, TX 78258
USA
Phone
Website
Email Address
Overview
ViroXis is a bio-pharmaceutical company focused on developing and commercializing innovative, proprietary, botanical pharmaceuticals derived from Sandalwood oil.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Alan Dean
Chief Executive Officer
Ian Clements
Chief Operating Officer
Jim Traa
Chief Scientific Officer
Corey Levenson
Co-Founder
Paul Castella
Browse more venture capital transactions:
Prev: 10/15/2010: Kabongo venture capital transaction
Next: 10/15/2010: EditRing venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs